4,132 Shares in Veeva Systems Inc. $VEEV Acquired by First Citizens Bank & Trust Co.

Key Points

• First Citizens Bank & Trust Co. acquired 4,132 Veeva shares worth approximately $1.18 million in the third quarter. Institutional investors collectively own 88.2% of Veeva’s outstanding stock.
• Analyst sentiment remains favorable, with a consensus “Moderate Buy” rating and average price target of $285.92; recent targets range as high as $300.
• Veeva reported quarterly earnings of $2.35 per share, exceeding estimates, while revenue rose 17.6% year over year to $927.96 million. The stock opened at $313.01, near its 52-week high.

First Citizens Bank & Trust Co. purchased a new position in shares of Veeva Systems Inc. (NYSE:VEEV - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,132 shares of the technology company's stock, valued at approximately $1,179,000.

Several other hedge funds also recently modified their holdings of the business. Principal Financial Group Inc. increased its position in Veeva Systems by 7.0% during the first quarter. Principal Financial Group Inc. now owns 4,141,545 shares of the technology company's stock worth $727,513,000 after acquiring an additional 271,252 shares during the period. Swedbank AB boosted its holdings in Veeva Systems by 43.5% in the 1st quarter. Swedbank AB now owns 1,645,128 shares of the technology company's stock valued at $288,983,000 after purchasing an additional 498,971 shares during the period. Pictet Asset Management Holding SA boosted its holdings in Veeva Systems by 43.6% in the 1st quarter. Pictet Asset Management Holding SA now owns 1,593,795 shares of the technology company's stock valued at $279,970,000 after purchasing an additional 483,720 shares during the period. Amundi boosted its holdings in Veeva Systems by 8.0% in the 1st quarter. Amundi now owns 992,977 shares of the technology company's stock valued at $174,426,000 after purchasing an additional 73,510 shares during the period. Finally, Arrowstreet Capital Limited Partnership boosted its holdings in Veeva Systems by 203.0% in the 1st quarter. Arrowstreet Capital Limited Partnership now owns 913,281 shares of the technology company's stock valued at $160,427,000 after purchasing an additional 611,868 shares during the period. 88.20% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several analysts have issued reports on the stock. Mizuho boosted their price objective on shares of Veeva Systems from $270.00 to $280.00 and gave the stock an "outperform" rating in a report on Thursday, August 27th. UBS Group upped their price objective on shares of Veeva Systems from $190.00 to $290.00 and gave the company a "neutral" rating in a research report on Thursday, August 27th. Morgan Stanley increased their target price on shares of Veeva Systems from $215.00 to $275.00 and gave the company an "equal weight" rating in a research note on Thursday, August 27th. Robert W. Baird lifted their target price on Veeva Systems from $260.00 to $300.00 and gave the stock an "outperform" rating in a research report on Thursday, August 27th. Finally, Jefferies Financial Group reissued a "buy" rating and set a $295.00 target price on shares of Veeva Systems in a research report on Thursday, August 27th. Nineteen equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $285.92.

Veeva Systems Trading Up 5.3%

VEEV opened at $313.01 on Friday. The stock's 50 day simple moving average is $268.19 and its 200-day simple moving average is $207.22. The stock has a market cap of $50.68 billion, a PE ratio of 51.48, a P/E/G ratio of 1.27 and a beta of 0.93. Veeva Systems Inc. has a 1 year low of $148.05 and a 1 year high of $315.02.

Veeva Systems (NYSE:VEEV - Get Free Report) last issued its earnings results on Wednesday, August 26th. The technology company reported $2.35 EPS for the quarter, topping the consensus estimate of $2.23 by $0.12. The firm had revenue of $927.96 million during the quarter, compared to analysts' expectations of $905.38 million. Veeva Systems had a return on equity of 14.25% and a net margin of 29.34%. Veeva Systems's quarterly revenue was up 17.6% compared to the same quarter last year. During the same period last year, the business earned $1.99 earnings per share. Veeva Systems has set its FY 2027 guidance at 9.210-9.210 EPS and its Q3 2027 guidance at 2.330-2.340 EPS. Equities analysts forecast that Veeva Systems Inc. will post 6.70 earnings per share for the current fiscal year.

Insider Transactions at Veeva Systems

In other news, Director Priscilla Hung sold 750 shares of the firm's stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $261.04, for a total transaction of $195,780.00. Following the completion of the transaction, the director directly owned 3,242 shares of the company's stock, valued at approximately $846,291.68. This trade represents a 18.79% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Thomas Schwenger sold 36,000 shares of Veeva Systems stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $250.23, for a total transaction of $9,008,280.00. Following the sale, the insider owned 19,449 shares in the company, valued at approximately $4,866,723.27. This trade represents a 64.92% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 51,591 shares of company stock valued at $13,355,945. Company insiders own 10.60% of the company's stock.

Key Headlines Impacting Veeva Systems

Here are the key news stories impacting Veeva Systems this week:

• Positive Sentiment: Expanded IQVIA partnership strengthens Veeva’s clinical-software position. IQVIA selected Veeva’s Clinical Trial Management System, eTMF, Study Startup, and Site Connect applications as enterprise standards across its global clinical studies. The agreement expands Veeva’s footprint with a major contract research organization and could support broader adoption among biopharma customers. Veeva Systems Becomes Default Clinical Software Across a Major Research Partner
• Positive Sentiment: Analyst support remains favorable. Oppenheimer maintained a $325 price target, and average brokerage recommendations remain optimistic. While analyst ratings can be biased, the continued positive stance is supporting investor confidence. Oppenheimer Keeps USD 325 Target for Veeva Systems Stock
• Positive Sentiment: Technical momentum attracted additional buying. Veeva moved above a buy point in an early-stage chart pattern, with reports describing increased institutional or “big money” exposure to the AI and life-sciences software theme. Veeva Stock Breaks Out as Big Money Grabs Exposure
• Positive Sentiment: Veeva’s growth platform continues to broaden. More than 175 emerging biotechs reportedly use Veeva Basics, adding to the company’s clinical, regulatory, and quality software ecosystem. Veeva also plans to hold a virtual investor day on November 5, which could provide additional detail on strategy and growth opportunities. Veeva to Host Virtual Investor Day
• Neutral Sentiment: Veeva is receiving elevated investor attention, and industry forecasts point to long-term expansion in life-sciences IT driven by cloud and artificial-intelligence adoption. These factors support the broader investment narrative but do not represent new company-specific revenue.
• Negative Sentiment: Oppenheimer noted that Veeva’s guidance may imply further deceleration in research-and-development growth. This could temper expectations and remains a risk for a stock trading at a premium valuation. Veeva Systems’ Research and Development Growth Tracking to Plan

Veeva Systems Company Profile

Veeva Systems Inc is a cloud software company that provides applications and services for the life sciences industry. Its customers include pharmaceutical, biotechnology, medical device and other organizations involved in developing, manufacturing and commercializing regulated products.

The company's product portfolio includes the Veeva Vault platform, which supports areas such as clinical operations, regulatory affairs, quality management, safety and medical communications. Veeva also offers commercial and customer relationship management applications, data and analytics products, and services designed to help life sciences companies manage relationships with healthcare professionals, oversee content and improve operational efficiency.

Founded in 2007, Veeva serves customers globally and has expanded its offerings from commercial software into research, development, manufacturing and quality processes.

Want to see what other hedge funds are holding VEEV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Veeva Systems Inc. (NYSE:VEEV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.